

# David Knopman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5527354/publications.pdf>

Version: 2024-02-01

634  
papers

82,252  
citations

813

118  
h-index

551

264  
g-index

649  
all docs

649  
docs citations

649  
times ranked

51448  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2023, 19, 4498-4506.	0.8	17
2	Association of Indication for Hospitalization With Subsequent Amyloid Positron Emission Tomography and Magnetic Resonance Imaging Biomarkers. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2023, 78, 304-313.	3.6	0
3	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. <i>Brain</i> , 2022, 145, 1079-1097.	7.6	30
4	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. <i>Alzheimer's and Dementia</i> , 2022, 18, 602-611.	0.8	20
5	Detection of Alzheimer's disease amyloid beta 1â€42, pâ€tau, and tâ€tau assays. <i>Alzheimer's and Dementia</i> , 2022, 18, 635-644.	0.8	28
6	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. <i>Alzheimer's and Dementia</i> , 2022, 18, 1128-1140.	0.8	88
7	The temporal onset of the core features in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2022, 18, 591-601.	0.8	19
8	The association of motoric cognitive risk with incident dementia and neuroimaging characteristics: The Atherosclerosis Risk in Communities Study. <i>Alzheimer's and Dementia</i> , 2022, 18, 434-444.	0.8	12
9	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. <i>Brain Communications</i> , 2022, 4, fcac017.	3.3	12
10	Association of Ischemic Stroke Incidence, Severity, and Recurrence With Dementia in the Atherosclerosis Risk in Communities Cohort Study. <i>JAMA Neurology</i> , 2022, 79, 271.	9.0	46
11	Relation of Diabetes Mellitus to Incident Dementia in Patients With Atrial Fibrillation (from the Tj ETQq1 1 0.784314 rgBT /Oyerlock 10	1.6	4
12	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2022, 112, 16-26.	3.1	9
13	Endurance and gait speed relationships with mild cognitive impairment and dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12281.	2.4	6
14	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. <i>NeuroImage: Clinical</i> , 2022, 34, 102954.	2.7	3
15	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. <i>Brain Communications</i> , 2022, 4, fcac013.	3.3	15
16	Association of Performance on the Financial Capacity Instrumentâ€“Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults. <i>Neurology: Clinical Practice</i> , 2022, 12, 113-124.	1.6	3
17	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. <i>Acta Neuropathologica Communications</i> , 2022, 10, 16.	5.2	14
18	Therapeutic Targets for Alzheimerâ€™s Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report. <i>Journal of prevention of Alzheimer's disease, The</i> , 2022, 9, 231-235.	2.7	2

#	ARTICLE	IF	CITATIONS
19	TDP-43 represses cryptic exon inclusion in the FTDâ€‘ALS gene UNC13A. <i>Nature</i> , 2022, 603, 124-130.	27.8	193
20	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a series of clinical cases. <i>Journal of Neurology</i> , 2022, 269, 4110-4128.	3.6	7
21	Alzheimer's disease and related dementias and heart failure: A community study. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 1664-1672.	2.6	12
22	A computational model of neurodegeneration in Alzheimerâ€™s disease. <i>Nature Communications</i> , 2022, 13, 1643.	12.8	32
23	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2022, 37, 1256-1264.	3.9	11
24	Poly (ADP-Ribose) and Î±-synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity. <i>PLoS ONE</i> , 2022, 17, e0264446.	2.5	6
25	Association of Carotid Intima-Media Thickness with Brain MRI Markers in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106388.	1.6	6
26	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging. <i>NeuroImage</i> , 2022, 251, 119020.	4.2	9
27	A longitudinal investigation of AÎ², anxiety, depression, and mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2022, 18, 1824-1831.	0.8	14
28	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimerâ€™s disease. <i>Acta Neuropathologica</i> , 2022, 143, 571-583.	7.7	3
29	Deep learning-based brain age prediction in normal aging and dementia. <i>Nature Aging</i> , 2022, 2, 412-424.	11.6	52
30	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. <i>Acta Neuropathologica</i> , 2022, 144, 159-160.	7.7	14
31	Artificial Intelligenceâ€‘Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. <i>Mayo Clinic Proceedings</i> , 2022, 97, 871-880.	3.0	6
32	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1537-1547.	2.6	4
33	Kidney-Metabolic Factors Associated with Cognitive Impairment in Chronic Kidney Disease: A Pilot Study. <i>American Journal of Nephrology</i> , 2022, 53, 435-445.	3.1	4
34	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. <i>Neurology</i> , 2022, , 10.1212/WNL.0000000000200582.	1.1	0
35	Performance of plasma phosphorylated tau 181 and 217 in the community. <i>Nature Medicine</i> , 2022, 28, 1398-1405.	30.7	114
36	Causal structure discovery identifies risk factors and early brain markers related to evolution of white matter hyperintensities. <i>NeuroImage: Clinical</i> , 2022, 35, 103077.	2.7	8

#	ARTICLE	IF	CITATIONS
37	Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldtâ€“Jakob disease and autoimmune encephalitis. <i>European Journal of Neurology</i> , 2022, 29, 2905-2912.	3.3	4
38	Associations of Vascular Risk and Amyloid Burden with Subsequent Dementia. <i>Annals of Neurology</i> , 2022, 92, 607-619.	5.3	10
39	Frequency of LATE neuropathologic change across the spectrum of Alzheimerâ€™s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. <i>Acta Neuropathologica</i> , 2022, 144, 27-44.	7.7	67
40	Neuropathologic scales of cerebrovascular disease associated with diffusion changes on MRI. <i>Acta Neuropathologica</i> , 2022, 144, 1117-1125.	7.7	11
41	Polygenic Scores of Alzheimerâ€™s Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1615-1625.	2.6	2
42	Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 179-191.	1.2	25
43	Distinguishing Frontotemporal Dementia From Alzheimer Disease Through Everyday Function Profiles: Trajectories of Change. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 66-75.	2.3	4
44	Association of Hospitalization with Longâ€“Term Cognitive Trajectories in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 660-668.	2.6	18
45	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. <i>NeuroImage</i> , 2021, 224, 117433.	4.2	63
46	Association of Initial Î²-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 217.	9.0	27
47	Brain volumetric deficits in <i>MAPT</i> mutation carriers: a multisite study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 95-110.	3.7	21
48	Brain MRI after critical care admission: A longitudinal imaging study. <i>Journal of Critical Care</i> , 2021, 62, 117-123.	2.2	7
49	Physical Activity and Trajectory of Cognitive Change in Older Persons: Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 377-388.	2.6	12
50	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 99, 11-18.	3.1	11
51	Association of Cortical and Subcortical Î²-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021, 33, 64-71.	1.8	9
52	Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. <i>Alzheimer's and Dementia</i> , 2021, 17, 696-701.	0.8	330
53	Mayo Normative Studies: Regression-Based Normative Data for the Auditory Verbal Learning Test for Ages 30â€“91 Years and the Importance of Adjusting for Sex. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 211-226.	1.8	33
54	Prospective Analysis of Leisure-Time Physical Activity in Midlife and Beyond and Brain Damage on MRI in Older Adults. <i>Neurology</i> , 2021, 96, e964-e974.	1.1	12

#	ARTICLE	IF	CITATIONS
55	$\beta^2$ -Amyloid PET and <sup>123</sup> I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. <i>Neurology</i> , 2021, 96, .	1.1	13
56	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. <i>NeuroImage: Clinical</i> , 2021, 31, 102754.	2.7	27
57	Gait Speed and Instrumental Activities of Daily Living in Older Adults After Hospitalization: A Longitudinal Population-Based Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, e272-e280.	3.6	1
58	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology. <i>Acta Neuropathologica Communications</i> , 2021, 9, 48.	5.2	18
59	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. <i>Alzheimer's and Dementia</i> , 2021, 17, 801-812.	0.8	18
60	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 683-693.	2.6	7
61	Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1362-1369.	2.7	16
62	Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462	0.8	16
63	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. <i>Brain Communications</i> , 2021, 3, fcab076.	3.3	13
64	<sup>1</sup> NIA's Alzheimer's Disease Framework: Clinical Characterization of Stages. <i>Annals of Neurology</i> , 2021, 89, 1145-1156.	5.3	31
65	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. <i>Brain Communications</i> , 2021, 3, fcab106.	3.3	38
66	Long-read targeted sequencing uncovers clinicopathological associations for <i>C9orf72</i> -linked diseases. <i>Brain</i> , 2021, 144, 1082-1088.	7.6	17
67	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.1	52
68	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 113-122.	2.6	8
69	Alzheimer disease. <i>Nature Reviews Disease Primers</i> , 2021, 7, 33.	30.5	784
70	Plasma amyloid $\beta^2$ levels are driven by genetic variants near <i>APOE</i> , <i>BACE1</i> , <i>APP</i> , <i>PSEN2</i> : A genome-wide association study in over 12,000 non-demented participants. <i>Alzheimer's and Dementia</i> , 2021, 17, 1663-1674.	0.8	20
71	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. <i>Journal of Neuroimaging</i> , 2021, 31, 1020-1027.	2.0	13
72	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. <i>NeuroImage</i> , 2021, 231, 117845.	4.2	38

#	ARTICLE	IF	CITATIONS
73	CSF dynamics as a predictor of cognitive progression. <i>NeuroImage</i> , 2021, 232, 117899.	4.2	3
74	Cognitive Heterogeneity in Alzheimer Clinical Trials. <i>Neurology</i> , 2021, 96, 1017-1018.	1.1	1
75	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. <i>Brain</i> , 2021, 144, 3212-3225.	7.6	26
76	Cerebral Microbleeds. <i>Stroke</i> , 2021, 52, 2347-2355.	2.0	9
77	Lack of physical activity, neuropsychiatric symptoms and the risk of incident mild cognitive impairment in older community-dwelling individuals. <i>German Journal of Exercise and Sport Research</i> , 2021, 51, 487-494.	1.2	5
78	Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks. <i>Neurology</i> , 2021, 97, 545-547.	1.1	25
79	Association of Midlife Plasma Amyloid- $\beta^2$ Levels With Cognitive Impairment in Late Life. <i>Neurology</i> , 2021, 97, e1123-e1131.	1.1	13
80	Revisiting FDA Approval of Aducanumab. <i>New England Journal of Medicine</i> , 2021, 385, 769-771.	27.0	104
81	Chronic Kidney Disease Associated with Worsening White Matter Disease and Ventricular Enlargement. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1729-1740.	2.6	3
82	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. <i>Brain Communications</i> , 2021, 3, fcab182.	3.3	12
83	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid- $\beta^2$ PET Signal. <i>Neurology</i> , 2021, 97, e1799-e1808.	1.1	10
84	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , 2021, 238, 118259.	4.2	24
85	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021, 78, 1108.	9.0	114
86	Brain White Matter Structure and Amyloid Deposition in Black and White Older Adults: The ARICâ€PET Study. <i>Journal of the American Heart Association</i> , 2021, 10, e022087.	3.7	7
87	A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimerâ€™s Disease Based on Cogstate One Card Learning Accuracy Performance. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 861-877.	2.6	7
88	<i>APOE3</i>-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. <i>Science Translational Medicine</i> , 2021, 13, eabc9375.	12.4	37
89	Sex Difference in the Relation Between Marital Status and Dementia Risk in Two Population-Based Cohorts. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1269-1279.	2.6	8
90	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2021, 105, 252-261.	3.1	18

#	ARTICLE	IF	CITATIONS
91	Young-Onset Dementia—New Insights for an Underappreciated Problem. JAMA Neurology, 2021, 78, 1055.	9.0	3
92	Relationships between $\beta$ -amyloid and tau in an elderly population: An accelerated failure time model. Neurolmage, 2021, 242, 118440.	4.2	15
93	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. Brain Communications, 2021, 3, fcaa238.	3.3	11
94	Alzheimer Disease Spectrum. Neurology, 2021, 96, 299-300.	1.1	5
95	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. Neurobiology of Aging, 2021, 110, 27-36.	3.1	7
96	The Relationship of APOE $\epsilon$ 4, Race, and Sex on the Age of Onset and Risk of Dementia. Frontiers in Neurology, 2021, 12, 735036.	2.4	11
97	Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA. Molecular Neurodegeneration, 2021, 16, 74.	10.8	10
98	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. Journal of Alzheimer's Disease, 2021, , 1-6.	2.6	1
99	White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12269.	2.4	1
100	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimer's Research and Therapy, 2021, 13, 199.	6.2	32
101	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.8	32
102	Chronic Systemic Inflammation Is Associated With Symptoms of Late-Life Depression: The ARIC Study. American Journal of Geriatric Psychiatry, 2020, 28, 87-98.	1.2	24
103	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.8	38
104	Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium. Alzheimer's and Dementia, 2020, 16, 79-90.	0.8	48
105	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. Alzheimer's and Dementia, 2020, 16, 22-36.	0.8	32
106	Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration. Alzheimer's and Dementia, 2020, 16, 91-105.	0.8	27
107	Association of Intracranial Atherosclerotic Disease With Brain $\beta$ -Amyloid Deposition. JAMA Neurology, 2020, 77, 350.	9.0	27
108	Linear vs volume measures of ventricle size. Neurology, 2020, 94, e549-e556.	1.1	19



#	ARTICLE	IF	CITATIONS
109	Cerebral microbleed incidence, relationship to amyloid burden. <i>Neurology</i> , 2020, 94, e190-e199.	1.1	31
110	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	10.2	175
111	Brain imaging measurements of fibrillar amyloid $\beta$ burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the <i>APOE</i> $\epsilon$ 4 allele. <i>Alzheimer's and Dementia</i> , 2020, 16, 598-609.	0.8	23
112	Incidence of frontotemporal disorders in Olmsted County: A population-based study. <i>Alzheimer's and Dementia</i> , 2020, 16, 482-490.	0.8	11
113	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 49-59.	0.8	27
114	Tau $\beta$ -positron emission tomography correlates with neuropathology findings. <i>Alzheimer's and Dementia</i> , 2020, 16, 561-571.	0.8	113
115	Longitudinal flortaucipir ([ <sup>18</sup> F]AV-1451) PET imaging in primary progressive apraxia of speech. <i>Cortex</i> , 2020, 124, 33-43.	2.4	5
116	$\beta$ -Amyloid PET and neuropathology in dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e282-e291.	1.1	65
117	$\beta$ -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. <i>Neurology</i> , 2020, 95, e3257-e3268.	1.1	62
118	Association of mid-life serum lipid levels with late-life brain volumes: The atherosclerosis risk in communities neurocognitive study (ARIC NCS). <i>NeuroImage</i> , 2020, 223, 117324.	4.2	5
119	Predicting future rates of tau accumulation on PET. <i>Brain</i> , 2020, 143, 3136-3150.	7.6	74
120	Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI. <i>Neurobiology of Aging</i> , 2020, 96, 176-183.	3.1	27
121	Variants in <i>PPP2R2B</i> and <i>IGF2BP3</i> are associated with higher tau deposition. <i>Brain Communications</i> , 2020, 2, fcaa159.	3.3	12
122	Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, 1115-1124.	0.8	11
123	Association of Hypertension According to New American College of Cardiology/American Heart Association Blood Pressure Guidelines With Incident Dementia in the ARIC Study Cohort. <i>Journal of the American Heart Association</i> , 2020, 9, e017546.	3.7	8
124	Artificial Intelligence–Electrocardiography to Predict Incident Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e009355.	4.8	68
125	Association Between Neuropsychiatric Symptoms and Functional Change in Older Non-Demented Adults: Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 911-917.	2.6	3
126	Dementia in late-onset epilepsy. <i>Neurology</i> , 2020, 95, e3248-e3256.	1.1	45



#	ARTICLE	IF	CITATIONS
127	Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2785-2793.	2.4	7
128	Extending Alzheimer disease biomarker studies into the Hispanic community. <i>Neurology</i> , 2020, 95, 665-666.	1.1	2
129	The Enigma of Decreasing Dementia Incidence. <i>JAMA Network Open</i> , 2020, 3, e2011199.	5.9	9
130	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. <i>JAMA Network Open</i> , 2020, 3, e2022847.	5.9	19
131	Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy. <i>Brain</i> , 2020, 143, 3463-3476.	7.6	45
132	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2020, 16, 1013-1022.	0.8	20
133	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1195-1205.	3.0	30
134	Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. <i>Brain Communications</i> , 2020, 2, fcaa068.	3.3	81
135	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. <i>Neurology</i> , 2020, 95, e23-e34.	1.1	27
136	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. <i>Brain</i> , 2020, 143, 2281-2294.	7.6	51
137	Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 261-274.	2.6	25
138	Mid- and Late-Life Leisure-Time Physical Activity and Global Brain Amyloid Burden: The Atherosclerosis Risk in Communities (ARIC)-PET Study. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 139-147.	2.6	4
139	Subtypes of dementia with Lewy bodies are associated with $\alpha$ -synuclein and tau distribution. <i>Neurology</i> , 2020, 95, e155-e165.	1.1	47
140	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. <i>British Journal of Anaesthesia</i> , 2020, 124, 594-602.	3.4	14
141	Preoperative cognitive impairment associated with oversedation during recovery from anesthesia. <i>Journal of Anesthesia</i> , 2020, 34, 390-396.	1.7	2
142	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. <i>Neurology</i> , 2020, 94, e1793-e1802.	1.1	28
143	Scientific Advising and Reviewing: On strengthening the bond between the Alzheimer's Association and the scientific community. <i>Alzheimer's and Dementia</i> , 2020, 16, 1095-1098.	0.8	0
144	Longitudinal structural and metabolic changes in frontotemporal dementia. <i>Neurology</i> , 2020, 95, e140-e154.	1.1	39

#	ARTICLE	IF	CITATIONS
145	CSF biomarkers in Olmsted County. <i>Neurology</i> , 2020, 95, e256-e267.	1.1	14
146	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. <i>Neurobiology of Aging</i> , 2020, 92, 135-140.	3.1	3
147	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa040.	3.3	17
148	An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis. <i>Alzheimer's and Dementia</i> , 2020, 16, 1582-1590.	0.8	18
149	A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals. <i>Scientific Reports</i> , 2020, 10, 3869.	3.3	26
150	Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. <i>Neurology</i> , 2020, 94, e1571-e1579.	1.1	18
151	Medical Doctors and Dementia: A Longitudinal Study. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1250-1255.	2.6	0
152	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. <i>Neurobiology of Aging</i> , 2020, 88, 42-50.	3.1	14
153	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 87, 556-567.	5.3	17
154	Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, 60-70.	0.8	27
155	Utility of the global CDR <sup>®</sup> plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. <i>Alzheimer's and Dementia</i> , 2020, 16, 106-117.	0.8	81
156	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1511-1523.	2.6	14
157	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. <i>Journal of Neurology</i> , 2020, 267, 1444-1453.	3.6	4
158	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 707-721.	3.7	17
159	Brain amyloid, cortical thickness, and changes in activities of daily living. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 474-485.	3.7	3
160	Association between transactive response DNA-binding protein of 43 kDa type and cognitive resilience to Alzheimer's disease: a case-control study. <i>Neurobiology of Aging</i> , 2020, 92, 92-97.	3.1	13
161	Plasma phospholipid very-long-chain SFAs in midlife and 20-year cognitive change in the Atherosclerosis Risk in Communities (ARIC): a cohort study. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 1252-1258.	4.7	11
162	The quest for dementia prevention does not include an aspirin a day. <i>Neurology</i> , 2020, 95, 105-106.	1.1	2

#	ARTICLE	IF	CITATIONS
163	Pick's disease: clinicopathologic characterization of 21 cases. <i>Journal of Neurology</i> , 2020, 267, 2697-2704.	3.6	17
164	Associations between cerebrospinal fluid total phosphatidylcholines, neurodegeneration, cognitive decline, and risk of mild cognitive impairment in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2020, 93, 52-54.	3.1	1
165	Albuminuria and Estimated GFR as Risk Factors for Dementia in Midlife and Older Age: Findings From the ARIC Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 775-783.	1.9	33
166	Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. <i>Journal of Clinical Investigation</i> , 2020, 130, 6080-6092.	8.2	117
167	Revised Self-Monitoring Scale. <i>Neurology</i> , 2020, 94, e2384-e2395.	1.1	23
168	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. <i>Neurology</i> , 2020, 95, e3190-e3202.	1.1	13
169	Associations Between Atrial Cardiopathy and Cerebral Amyloid: The ARIC-PET Study. <i>Journal of the American Heart Association</i> , 2020, 9, e018399.	3.7	14
170	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 877-883.	3.6	16
171	Association of non-exercise physical activity in mid- and late-life with cognitive trajectories and the impact of APOE $\epsilon$ 4 genotype status: the Mayo Clinic Study of Aging. <i>European Journal of Ageing</i> , 2019, 16, 491-502.	2.8	9
172	Association of Midlife to Late-Life Blood Pressure Patterns With Incident Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 535.	7.4	227
173	Informant-based hearing difficulties and the risk for mild cognitive impairment and dementia. <i>Age and Ageing</i> , 2019, 48, 888-894.	1.6	13
174	Rates of lobar atrophy in asymptomatic <i>MAPT</i> mutation carriers. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 338-346.	3.7	22
175	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging's Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	9.0	182
176	High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 2353-2361.	2.6	7
177	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1516-1523.	3.0	35
178	Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults. <i>British Journal of Anaesthesia</i> , 2019, 123, 808-817.	3.4	13
179	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. <i>Acta Neuropathologica Communications</i> , 2019, 7, 150.	5.2	40
180	Associations Between Left Ventricular Structure, Function, and Cerebral Amyloid. <i>Stroke</i> , 2019, 50, 3622-3624.	2.0	8

#	ARTICLE	IF	CITATIONS
181	Association of Apolipoprotein E $\epsilon$ 4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. <i>JAMA Network Open</i> , 2019, 2, e1913909.	5.9	41
182	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. <i>Annals of Neurology</i> , 2019, 86, 866-877.	5.3	40
183	Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 104451.	1.6	1
184	Comparison of variables associated with cerebrospinal fluid neurofilament, total $\tau$ , and neurogranin. <i>Alzheimer's and Dementia</i> , 2019, 15, 1437-1447.	0.8	38
185	Population-Based Evaluation of Lumbar Puncture Opening Pressures. <i>Frontiers in Neurology</i> , 2019, 10, 899.	2.4	25
186	Automatic extraction and assessment of lifestyle exposures for Alzheimer's disease using natural language processing. <i>International Journal of Medical Informatics</i> , 2019, 130, 103943.	3.3	18
187	The bivariate distribution of amyloid- $\beta$ 2 and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	7.6	129
188	Cognitive function after surgery with regional or general anesthesia: A population-based study. <i>Alzheimer's and Dementia</i> , 2019, 15, 1243-1252.	0.8	13
189	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. <i>Stroke</i> , 2019, 50, 3037-3044.	2.0	39
190	Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volume—Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2431-2436.	2.4	8
191	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. <i>Brain</i> , 2019, 142, 3621-3635.	7.6	37
192	Association of white matter microstructural integrity with cognition and dementia. <i>Neurobiology of Aging</i> , 2019, 83, 63-72.	3.1	32
193	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. <i>Neurobiology of Aging</i> , 2019, 83, 54-62.	3.1	14
194	Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. <i>Brain</i> , 2019, 142, 443-459.	7.6	65
195	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. <i>Neurobiology of Aging</i> , 2019, 77, 26-36.	3.1	51
196	Neuroimaging findings in midlife and risk of late-life dementia over 20 years of follow-up. <i>Neurology</i> , 2019, 92, e917-e923.	1.1	16
197	The Association of Late-Life Diabetes Status and Hyperglycemia With Incident Mild Cognitive Impairment and Dementia: The ARIC Study. <i>Diabetes Care</i> , 2019, 42, 1248-1254.	8.6	104
198	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	7.7	87

#	ARTICLE	IF	CITATIONS
199	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. <i>Brain</i> , 2019, 142, 2466-2482.	7.6	33
200	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2316.	7.4	223
201	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenocopy in Mapt Mutation Carriers. <i>Journal of Neuroimaging</i> , 2019, 29, 624-629.	2.0	9
202	Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2019, 15, 878-887.	0.8	41
203	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 927-939.	0.8	48
204	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. <i>Neurology</i> , 2019, 93, e29-e39.	1.1	62
205	Plasma and CSF neurofilament light. <i>Neurology</i> , 2019, 93, e252-e260.	1.1	160
206	White matter hyperintensities: relationship to amyloid and tau burden. <i>Brain</i> , 2019, 142, 2483-2491.	7.6	126
207	Association of Brain Magnetic Resonance Imaging Signs With Cognitive Outcomes in Persons With Nonimpaired Cognition and Mild Cognitive Impairment. <i>JAMA Network Open</i> , 2019, 2, e193359.	5.9	45
208	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 23, 101823.	2.7	54
209	A brief history of "Alzheimer disease". <i>Neurology</i> , 2019, 92, 1053-1059.	1.1	52
210	Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa. <i>Alzheimer's and Dementia</i> , 2019, 15, 799-806.	0.8	14
211	Plasma Metabolites Associated with Brain MRI Measures of Neurodegeneration in Older Adults in the Atherosclerosis Risk in Communities "Neurocognitive Study (ARIC-NCS). <i>International Journal of Molecular Sciences</i> , 2019, 20, 1744.	4.1	7
212	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. <i>Brain</i> , 2019, 142, 1134-1147.	7.6	72
213	Lowering of Amyloid-Beta by $\beta$ -Secretase Inhibitors " Some Informative Failures. <i>New England Journal of Medicine</i> , 2019, 380, 1476-1478.	27.0	56
214	Cortical $\beta$ -amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. <i>Translational Psychiatry</i> , 2019, 9, 123.	4.8	54
215	Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2019, 79, 43-49.	3.1	7
216	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 1144-1153.	3.9	98

#	ARTICLE	IF	CITATIONS
217	Neural correlates of domain-specific cognitive decline. <i>Neurology</i> , 2019, 92, e1051-e1063.	1.1	12
218	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	7.7	90
219	Cognitive Reserve in Midlife is not Associated with Amyloid- $\beta^2$ Deposition in Late-Life. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 517-521.	2.6	9
220	Entorhinal cortex tau, amyloid- $\beta^2$ , cortical thickness and memory performance in non-demented subjects. <i>Brain</i> , 2019, 142, 1148-1160.	7.6	68
221	ICâ€Pâ€127: VARIABILITY IN MRI AND PET MEASUREMENTS INTRODUCED BY CHANGE IN MRI VENDOR. <i>Alzheimer's and Dementia</i> , 2019, 15, P104.	0.8	3
222	Functional Activity and Neuropsychiatric Symptoms in Normal Aging and Mild Cognitive Impairment. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 68-71.	1.3	8
223	Quantity and quality of mental activities and the risk of incident mild cognitive impairment. <i>Neurology</i> , 2019, 93, e548-e558.	1.1	38
224	Cerebrospinal fluid dynamics disorders. <i>Neurology</i> , 2019, 93, e2237-e2246.	1.1	19
225	Association Between Critical Care Admissions and Cognitive Trajectories in Older Adults*. <i>Critical Care Medicine</i> , 2019, 47, 1116-1124.	0.9	20
226	Association of Dietary Patterns in Midlife and Cognitive Function in Later Life in US Adults Without Dementia. <i>JAMA Network Open</i> , 2019, 2, e1916641.	5.9	22
227	Association of Longitudinal $\beta^2$ -Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. <i>JAMA Network Open</i> , 2019, 2, e1916439.	5.9	22
228	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. <i>Acta Neuropathologica</i> , 2019, 137, 227-238.	7.7	65
229	Cerebral microbleeds. <i>Neurology</i> , 2019, 92, e253-e262.	1.1	53
230	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. <i>JAMA Neurology</i> , 2019, 76, 187.	9.0	66
231	Retinal signs and risk of incident dementia in the Atherosclerosis Risk in Communities study. <i>Alzheimer's and Dementia</i> , 2019, 15, 477-486.	0.8	31
232	Impaired Lung Function, Lung Disease, and Risk of Incident Dementia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1385-1396.	5.6	77
233	MRI Outperforms [18F]AVâ€1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 105-113.	3.9	33
234	Bad news and good news in AD, and how to reconcile them. <i>Nature Reviews Neurology</i> , 2019, 15, 61-62.	10.1	35

#	ARTICLE	IF	CITATIONS
235	<sup>18</sup> AV-1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. <i>Movement Disorders</i> , 2019, 34, 344-352.	3.9	26
236	The influence of $\beta^2$ -amyloid on [ <sup>18</sup> F]AV-1451 in semantic variant of primary progressive aphasia. <i>Neurology</i> , 2019, 92, e710-e722.	1.1	10
237	Early-Phase Randomized Clinical Trials—Expectations vs Hard Reality. <i>JAMA Neurology</i> , 2019, 76, 15.	9.0	0
238	Leisure-time physical activity sustained since midlife and preservation of cognitive function: The Atherosclerosis Risk in Communities Study. <i>Alzheimer's and Dementia</i> , 2019, 15, 273-281.	0.8	44
239	Predicting Progression to Mild Cognitive Impairment. <i>Annals of Neurology</i> , 2019, 85, 155-160.	5.3	32
240	Comparison of PC and iPad administrations of the Cogstate Brief Battery in the Mayo Clinic Study of Aging: Assessing cross-modality equivalence of computerized neuropsychological tests. <i>Clinical Neuropsychologist</i> , 2019, 33, 1102-1126.	2.3	13
241	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 181-195.	2.6	48
242	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. <i>NeuroImage: Clinical</i> , 2019, 21, 101605.	2.7	29
243	The Cross-sectional and Longitudinal Associations Between IL-6, IL-10, and TNF $\alpha$ and Cognitive Outcomes in the Mayo Clinic Study of Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1289-1295.	3.6	42
244	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 355.	3.4	25
245	Relationship Between Domain-Specific Cognitive Function and Speech-in-Noise Performance in Older Adults: The Atherosclerosis Risk in Communities Hearing Pilot Study. <i>American Journal of Audiology</i> , 2019, 28, 1006-1014.	1.2	12
246	Systemic inflammation during midlife and cognitive change over 20 years. <i>Neurology</i> , 2019, 92, e1256-e1267.	1.1	116
247	Frontal lobe <sup>1</sup> H MR spectroscopy in asymptomatic and symptomatic <i>MAPT</i> mutation carriers. <i>Neurology</i> , 2019, 93, e758-e765.	1.1	18
248	The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2018, 66, 68-74.	3.1	30
249	Recurrent perseverations on semantic verbal fluency tasks as an early marker of cognitive impairment. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018, 40, 832-840.	1.3	19
250	Joint associations of $\beta^2$ -amyloidosis and cortical thickness with cognition. <i>Neurobiology of Aging</i> , 2018, 65, 121-131.	3.1	27
251	Retinal signs and 20-year cognitive decline in the Atherosclerosis Risk in Communities Study. <i>Neurology</i> , 2018, 90, e1158-e1166.	1.1	29
252	Measuring cognition and function in the preclinical stage of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 64-75.	3.7	87



#	ARTICLE	IF	CITATIONS
253	White Matter Reference Region in PET Studies of <sup>11</sup> C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid- $\beta$ Deposition. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1583-1589.	5.0	37
254	Microinfarcts and blood pressure trajectories: response to Dr Niu et al.. <i>Journal of Human Hypertension</i> , 2018, 32, 385-385.	2.2	0
255	Frequency of Acute and Subacute Infarcts in a Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2018, 93, 300-306.	3.0	5
256	Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid- $\beta$ -positron emission tomography. <i>Alzheimer's and Dementia</i> , 2018, 14, 989-997.	0.8	386
257	Leisure-Time Physical Activity and the Risk of Incident Dementia: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 149-155.	2.6	33
258	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. <i>Alzheimer's and Dementia</i> , 2018, 14, 563-575.	0.8	98
259	Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 210-216.	2.4	19
260	[ <sup>18</sup> F]AV-1451 tau-PET and primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 83, 599-611.	5.3	73
261	Sifting through a failed Alzheimer trial. <i>Neurology</i> , 2018, 90, 447-448.	1.1	6
262	Tau-negative amnesic dementia masquerading as Alzheimer disease dementia. <i>Neurology</i> , 2018, 90, e940-e946.	1.1	24
263	In vivo <sup>18</sup> F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. <i>Neurology</i> , 2018, 90, e947-e954.	1.1	60
264	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. <i>Neurology</i> , 2018, 90, e466-e473.	1.1	55
265	Midlife cardiovascular health and 20-year cognitive decline: Atherosclerosis Risk in Communities Study results. <i>Alzheimer's and Dementia</i> , 2018, 14, 579-589.	0.8	60
266	[ <sup>18</sup> F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 83, 248-257.	5.3	67
267	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. <i>Brain</i> , 2018, 141, 271-287.	7.6	218
268	Prevalence and Risk of Severe Cognitive Impairment in Advanced Chronic Kidney Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 393-399.	3.6	27
269	Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 1244-1250.	3.6	30
270	The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study. <i>Neurobiology of Aging</i> , 2018, 68, 26-33.	3.1	59

#	ARTICLE	IF	CITATIONS
271	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. <i>JAMA Neurology</i> , 2018, 75, 970.	9.0	116
272	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	10.2	97
273	Olfactory function and neurocognitive outcomes in old age: The Atherosclerosis Risk in Communities Neurocognitive Study. <i>Alzheimer's and Dementia</i> , 2018, 14, 1015-1021.	0.8	21
274	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1005-1014.	0.8	80
275	Disrupted functional connectivity in primary progressive apraxia of speech. <i>NeuroImage: Clinical</i> , 2018, 18, 617-629.	2.7	36
276	Arterial stiffness and dementia pathology. <i>Neurology</i> , 2018, 90, e1248-e1256.	1.1	114
277	Association of Excessive Daytime Sleepiness With Longitudinal $\beta$ -Amyloid Accumulation in Elderly Persons Without Dementia. <i>JAMA Neurology</i> , 2018, 75, 672.	9.0	150
278	FDG-PET in tau-negative amnesic dementia resembles that of autopsy-proven hippocampal sclerosis. <i>Brain</i> , 2018, 141, 1201-1217.	7.6	67
279	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 739-749.	3.0	34
280	Sleep characteristics and risk of dementia and Alzheimer's disease: The Atherosclerosis Risk in Communities Study. <i>Alzheimer's and Dementia</i> , 2018, 14, 157-166.	0.8	122
281	Association of midlife lipids with 20-year cognitive change: A cohort study. <i>Alzheimer's and Dementia</i> , 2018, 14, 167-177.	0.8	84
282	Association Between Microinfarcts and Blood Pressure Trajectories. <i>JAMA Neurology</i> , 2018, 75, 212.	9.0	15
283	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. <i>International Psychogeriatrics</i> , 2018, 30, 245-251.	1.0	52
284	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. <i>Journal of Neuro-Oncology</i> , 2018, 136, 373-378.	2.9	9
285	01-03-05: ENTORHINAL CORTEX TAU PET, CORTICAL THICKNESS AND MEMORY PERFORMANCE IN COGNITIVELY UNIMPAIRED PERSONS. <i>Alzheimer's and Dementia</i> , 2018, 14, P221.	0.8	0
286	The Telephone Interview for Cognitive Status. <i>Cognitive and Behavioral Neurology</i> , 2018, 31, 158-158.	0.9	8
287	Amyloid- and tau-PET imaging in a familial prion kindred. <i>Neurology: Genetics</i> , 2018, 4, e290.	1.9	4
288	P2-334: THE INFLUENCE OF BETA-AMYLOID ON THE PROGRESSION OF PROGRESSIVE APRAXIA OF SPEECH. <i>Alzheimer's and Dementia</i> , 2018, 14, P810.	0.8	1

#	ARTICLE	IF	CITATIONS
289	Effect of Cognitive Status on the Receipt of Procedures Requiring Anesthesia and Critical Care Admissions in Older Adults. Mayo Clinic Proceedings, 2018, 93, 1552-1562.	3.0	7
290	Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. Journal of the American Geriatrics Society, 2018, 66, 2274-2281.	2.6	10
291	The Association of Mid- and Late-Life Systemic Inflammation with Brain Amyloid Deposition: The ARIC-PET Study. Journal of Alzheimer's Disease, 2018, 66, 1041-1052.	2.6	20
292	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	5.3	49
293	Genome-wide association study of 23,500 individuals identifies 7 loci associated with brain ventricular volume. Nature Communications, 2018, 9, 3945.	12.8	31
294	Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Annals of Clinical and Translational Neurology, 2018, 5, 1250-1263.	3.7	40
295	Association of Hospitalization, Critical Illness, and Infection with Brain Structure in Older Adults. Journal of the American Geriatrics Society, 2018, 66, 1919-1926.	2.6	14
296	Association of Apolipoprotein E $\epsilon$ 4 With Transactive Response DNA-Binding Protein 43. JAMA Neurology, 2018, 75, 1347.	9.0	60
297	Recommendations for the nomenclature of cognitive change associated with anaesthesia and surgeryâ€”2018. Acta Anaesthesiologica Scandinavica, 2018, 62, 1473-1480.	1.6	19
298	Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1345-1352.	2.6	23
299	Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications, 2018, 9, 2098.	12.8	484
300	Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: The Atherosclerosis Risk in Communities Study. Alzheimer's and Dementia, 2018, 14, 1406-1415.	0.8	74
301	Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. Journal of Alzheimer's Disease, 2018, 64, 281-290.	2.6	22
302	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947.	2.7	31
303	Subjective cognitive decline and risk of MCI. Neurology, 2018, 91, e300-e312.	1.1	176
304	TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnesic Alzheimer's Disease Dementia. Journal of Alzheimer's Disease, 2018, 64, 1227-1233.	2.6	20
305	Non-right handed primary progressive apraxia of speech. Journal of the Neurological Sciences, 2018, 390, 246-254.	0.6	4
306	Serum Vitamin D Concentrations and Cognitive Change Over 20 Years: The Atherosclerosis Risk in Communities Neurocognitive Study. Neuroepidemiology, 2018, 51, 131-137.	2.3	18

#	ARTICLE	IF	CITATIONS
307	<i>APOE</i> $\epsilon$ 4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. <i>Neurology</i> , 2018, 91, e1182-e1195.	1.1	122
308	Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1114-1120.	2.7	25
309	Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 351-358.	1.3	241
310	Duration and Pathologic Correlates of Lewy Body Disease. <i>JAMA Neurology</i> , 2017, 74, 310.	9.0	48
311	A robust biomarker of large-scale network failure in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 152-161.	2.4	29
312	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). <i>Acta Neuropathologica</i> , 2017, 133, 705-715.	7.7	125
313	Association Between Mentally Stimulating Activities in Late Life and the Outcome of Incident Mild Cognitive Impairment, With an Analysis of the <i>APOE</i> $\epsilon$ 4 Genotype. <i>JAMA Neurology</i> , 2017, 74, 332.	9.0	71
314	Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1443.	7.4	451
315	Contributions of imprecision in $\text{PET} \leftarrow \text{MRI}$ rigid registration to imprecision in amyloid $\text{PET} \leftarrow \text{SUVR}$ measurements. <i>Human Brain Mapping</i> , 2017, 38, 3323-3336.	3.6	26
316	Letter to the Editor re: Nexus of Cancer & Alzheimer's. <i>Alzheimer's and Dementia</i> , 2017, 13, 722-722.	0.8	1
317	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. <i>JAMA Neurology</i> , 2017, 74, 718.	9.0	107
318	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. <i>JAMA Neurology</i> , 2017, 74, 801.	9.0	81
319	Age-specific and sex-specific prevalence of cerebral $\beta$ -amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2017, 16, 435-444.	10.2	241
320	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. <i>Acta Neuropathologica</i> , 2017, 134, 255-269.	7.7	76
321	Beyond clinical syndromes in primary progressive aphasia. <i>Neurology</i> , 2017, 88, 2244-2245.	1.1	2
322	Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a population-based sample. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 127-130.	2.4	6
323	Cerebrovascular disease affects brain structural integrity long before clinically overt strokes. <i>Neurology</i> , 2017, 89, 110-111.	1.1	6
324	Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals. <i>Annals of Neurology</i> , 2017, 81, 871-882.	5.3	51

#	ARTICLE	IF	CITATIONS
325	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 172-179.	3.1	158
326	Alzheimer Disease. <i>Mayo Clinic Proceedings</i> , 2017, 92, 978-994.	3.0	57
327	Intracranial atherosclerosis and dementia. <i>Neurology</i> , 2017, 88, 1556-1563.	1.1	64
328	Association of Central Arterial Stiffness and Pressure Pulsatility with Mild Cognitive Impairment and Dementia: The Atherosclerosis Risk in Communities Study-Neurocognitive Study (ARIC-NCS). <i>Journal of Alzheimer's Disease</i> , 2017, 57, 195-204.	2.6	53
329	A phase 3 trial of IV immunoglobulin for Alzheimer disease. <i>Neurology</i> , 2017, 88, 1768-1775.	1.1	136
330	Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation. <i>Alzheimer's and Dementia</i> , 2017, 13, 267-273.	0.8	35
331	Incident Heart Failure and Cognitive Decline: The Atherosclerosis Risk in Communities Study. <i>Journal of Cardiac Failure</i> , 2017, 23, 47-55.	1.7	11
332	Tauâ€PET uptake: Regional variation in average SUVR and impact of amyloid deposition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 21-30.	2.4	86
333	Prevalence and Natural History of Superficial Siderosis. <i>Stroke</i> , 2017, 48, 3210-3214.	2.0	40
334	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. <i>Cortex</i> , 2017, 97, 143-159.	2.4	162
335	Midlife systemic inflammatory markers are associated with late-life brain volume. <i>Neurology</i> , 2017, 89, 2262-2270.	1.1	97
336	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. <i>Annals of Neurology</i> , 2017, 82, 706-718.	5.3	136
337	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 736-743.	2.2	7
338	Neuroimaging Correlates of Cerebral Microbleeds. <i>Stroke</i> , 2017, 48, 2964-2972.	2.0	63
339	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. <i>Neurology</i> , 2017, 89, 2039-2048.	1.1	15
340	Diabetes, Prediabetes, and Brain Volumes and Subclinical Cerebrovascular Disease on MRI: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). <i>Diabetes Care</i> , 2017, 40, 1514-1521.	8.6	81
341	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. <i>Lancet Neurology</i> , The, 2017, 16, 917-924.	10.2	159
342	Patients come from populations and populations contain patients. A two-stage scientific and ethics review: The next adaptation for single institutional review boards. , 2017, 13, 940-946.		11

#	ARTICLE	IF	CITATIONS
343	Midlife and Late-Life Vascular Risk Factors and White Matter Microstructural Integrity: The Atherosclerosis Risk in Communities Neurocognitive Study. Journal of the American Heart Association, 2017, 6, .	3.7	54
344	Correlates of Dementia and Mild Cognitive Impairment in Patients With Atrial Fibrillation: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCNS). Journal of the American Heart Association, 2017, 6, .	3.7	46
345	Decreased Glutamate Levels in Patients with Amnesic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB-PET Study. Journal of Neuroimaging, 2017, 27, 630-636.	2.0	29
346	Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. JAMA Neurology, 2017, 74, 1246.	9.0	404
347	Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2017, 58, 1273-1281.	2.6	15
348	Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease. Stroke, 2017, 48, 3196-3202.	2.0	83
349	Alzheimer's Disease-Related Dementias Summit 2016: National research priorities. Neurology, 2017, 89, 2381-2391.	1.1	109
350	Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. JAMA Neurology, 2017, 74, 1073.	9.0	149
351	Abnormal expression of homeobox genes and transthyretin in <i>C9ORF72</i> expansion carriers. Neurology: Genetics, 2017, 3, e161.	1.9	12
352	Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 1-10.	2.4	29
353	Aβ451 tau and Aβ42 amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	5.3	152
354	Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. Clinical Neuropsychologist, 2017, 31, 99-117.	2.3	47
355	Genetic variants associated with risk of Alzheimer's disease contribute to cognitive change in midlife: The Atherosclerosis Risk in Communities Study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 269-282.	1.7	19
356	Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Medicine, 2017, 32, 236-243.	1.6	79
357	Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. Alzheimer's and Dementia, 2017, 13, 168-177.	0.8	110
358	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.8	41
359	Detecting clinical change with the CDR-FTLD: differences between FTLD and AD dementia. International Journal of Geriatric Psychiatry, 2017, 32, 977-982.	2.7	17
360	Cortical Thickness and Anxiety Symptoms Among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Neuropsychiatry and Clinical Neurosciences, 2017, 29, 60-66.	1.8	16

#	ARTICLE	IF	CITATIONS
361	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.8	581
362	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 83-91.	3.7	94
363	Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging. Journal of the American Geriatrics Society, 2017, 65, 792-799.	2.6	41
364	[P2â€“415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2017, 13, P792.	0.8	33
365	[P4â€“015]: INTERNATIONAL SCIENTIFIC, ETHICAL AND REGULATORY REVIEW FOR ALZHEIMER'S CLINICAL TRIALS. Alzheimer's and Dementia, 2017, 13, P1259.	0.8	0
366	[ICâ€“Pâ€“122]: THE MAYO CLINIC ADULT LIFE SPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFE SPAN. Alzheimer's and Dementia, 2017, 13, P93.	0.8	22
367	[O1â€“09â€“02]: RELATIONSHIPS OF VERY SMALL, INFARCTâ€“LIKE LESIONS WITH 20â€“YEAR COGNITIVE DECLINE: THE ARIC STUDY. Alzheimer's and Dementia, 2017, 13, P211.	0.8	0
368	[O1â€“12â€“05]: CONTINUOUS MEASURES OF Î²â€“AMYLOIDOSIS AND CORTICAL THICKNESS IN RELATION TO COGNITIVE DECLINE IN COGNITIVELY NORMAL INDIVIDUALS: A POPULATIONâ€“BASED STUDY. Alzheimer's and Dementia, 2017, 13, P223.	0.8	0
369	[O2â€“12â€“04]: EFFECTS OF CEREBROVASCULAR INFARCT BURDEN ON COGNITIVE DECLINE IN THE PRESENCE OF DEMENTIA AND DEATH: ACCOUNTING FOR POTENTIALLY INFORMATIVE DROPOUT USING COMPETING RISK SHARED PARAMETER MODELS: THE ARIC STUDY. Alzheimer's and Dementia, 2017, 13, P586.	0.8	0
370	<sup>1</sup> H-MRS metabolites and rate of Î² <sup>2</sup> -amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.1	18
371	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. Neurology: Genetics, 2017, 3, e201.	1.9	2
372	Prognosis of Patients with Behavioral Variant Frontotemporal Dementia Who have Focal Versus		



#	ARTICLE	IF	CITATIONS
379	FTS3â€01â€02: Epidemiology of Vascular Related Risk Factors for Dementia. Alzheimer's and Dementia, 2016, 12, P276.	0.8	0
380	O2â€08â€01: Av1451 Pet Imaging in the Spectrum of Alzheimer's Disease from Clinically Normal to Dementia. Alzheimer's and Dementia, 2016, 12, P243.	0.8	0
381	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
382	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiology of Aging, 2016, 45, 107-108.	3.1	21
383	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. Alzheimer's and Dementia, 2016, 12, 510-515.	0.8	23
384	Multimorbidity and neuroimaging biomarkers among cognitively normal persons. Neurology, 2016, 86, 2077-2084.	1.1	27
385	Lifeâ€course blood pressure in relation to brain volumes. Alzheimer's and Dementia, 2016, 12, 890-899.	0.8	59
386	Social support and cognition in a community-based cohort: the Atherosclerosis Risk in Communities (ARIC) study. Age and Ageing, 2016, 45, 475-480.	1.6	40
387	Network-driven plasma proteomics expose molecular changes in the Alzheimerâ€™s brain. Molecular Neurodegeneration, 2016, 11, 31.	10.8	34
388	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism and Related Disorders, 2016, 28, 41-48.	2.2	33
389	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	14.8	213
390	Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension, 2016, 68, e67-e94.	2.7	482
391	Preclinical Alzheimer disease â€” the new frontier. Nature Reviews Neurology, 2016, 12, 620-621.	10.1	7
392	The ARIC-PET amyloid imaging study. Neurology, 2016, 87, 473-480.	1.1	119
393	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	3.1	69
394	Spt4 selectively regulates the expression of <i>C9orf72</i> sense and antisense mutant transcripts. Science, 2016, 353, 708-712.	12.6	116
395	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	1.9	16
396	An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58.	5.2	388

#	ARTICLE	IF	CITATIONS
397	Comparison of Gait Parameters for Predicting Cognitive Decline: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2016, 55, 559-567.	2.6	79
398	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	2.2	30
399	Amyloid- $\beta$ deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750.	7.6	68
400	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698.	1.1	22
401	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42.	3.1	20
402	Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimer's and Dementia, 2016, 12, 1226-1234.	0.8	107
403	Characterizing cognitive performance in a large longitudinal study of aging with computerized semantic indices of verbal fluency. Neuropsychologia, 2016, 89, 42-56.	1.6	31
404	Behavioral Variant Frontotemporal Dementia. JAMA Neurology, 2016, 73, 1051.	9.0	0
405	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. Neurology, 2016, 87, 2317-2323.	1.1	44
406	Timing of Physical Activity, Apolipoprotein E $\epsilon$ 4 Genotype, and Risk of Incident Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2016, 64, 2479-2486.	2.6	23
407	Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NC). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 73-82.	2.4	57
408	$\epsilon$ MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.8	32
409	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	3.9	32
410	Association of Mild Cognitive Impairment With Exposure to General Anesthesia for Surgical and Nonsurgical Procedures. Mayo Clinic Proceedings, 2016, 91, 208-217.	3.0	55
411	Suspected non-Alzheimer disease pathophysiology "concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	10.1	230
412	Cascading network failure across the Alzheimer's disease spectrum. Brain, 2016, 139, 547-562.	7.6	401
413	Mild cognitive impairment and dementia prevalence: The Atherosclerosis Risk in Communities Neurocognitive Study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 1-11.	2.4	209
414	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurology, The, 2016, 15, 56-64.	10.2	104

#	ARTICLE	IF	CITATIONS
415	The Brain in Kidney Disease (BRINK) Cohort Study: Design and Baseline Cognitive Function. American Journal of Kidney Diseases, 2016, 67, 593-600.	1.9	42
416	Effect of intellectual enrichment on AD biomarker trajectories. Neurology, 2016, 86, 1128-1135.	1.1	71
417	Decline in Weight and Incident Mild Cognitive Impairment. JAMA Neurology, 2016, 73, 439.	9.0	89
418	Influence of amyloid and <i>APOE</i> on cognitive performance in a late middle-aged cohort. Alzheimer's and Dementia, 2016, 12, 281-291.	0.8	45
419	Association Between Olfactory Dysfunction and Amnesic Mild Cognitive Impairment and Alzheimer Disease Dementia. JAMA Neurology, 2016, 73, 93.	9.0	294
420	Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimer's and Dementia, 2016, 12, 391-398.	0.8	58
421	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. JAMA Neurology, 2016, 73, 85.	9.0	160
422	The role of cerebrovascular disease when there is concomitant Alzheimer disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 952-956.	3.8	41
423	Diabetes is Associated with Worse Executive Function in Both Eastern and Western Populations: Shanghai Aging Study and Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2015, 47, 167-176.	2.6	23
424	Mortality in Mild Cognitive Impairment Varies by Subtype, Sex, and Lifestyle Factors: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2015, 45, 1237-1245.	2.6	41
425	Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by <i>APOE</i> $\epsilon$ 4 Allele. Frontiers in Aging Neuroscience, 2015, 7, 172.	3.4	6
426	Smoking and white matter hyperintensity progression. Neurology, 2015, 84, 841-848.	1.1	70
427	F4-03-03: Interpretation of delayed start trial data: Implications for researchers, clinicians, and patients. , 2015, 11, P262-P263.		0
428	Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. Neurobiology of Aging, 2015, 36, 1765.e7-1765.e16.	3.1	82
429	Two Authors Reply. American Journal of Epidemiology, 2015, 181, 292-293.	3.4	0
430	Clinicopathologic and <sup>11</sup> C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain, 2015, 138, 1370-1381.	7.6	270
431	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism and Related Disorders, 2015, 21, 1101-1104.	2.2	27
432	Neuropsychiatric symptoms, <i>APOE</i> $\epsilon$ 4, and the risk of incident dementia. Neurology, 2015, 84, 935-943.	1.1	101

#	ARTICLE	IF	CITATIONS
433	Risk and protective factors for cognitive impairment in persons aged 85 years and older. <i>Neurology</i> , 2015, 84, 1854-1861.	1.1	61
434	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. <i>Brain</i> , 2015, 138, 761-771.	7.6	222
435	Age, Sex, and $\text{APOE}\epsilon 4$ Effects on Memory, Brain Structure, and $\text{A}\beta$ -Amyloid Across the Adult Life Span. <i>JAMA Neurology</i> , 2015, 72, 511.	9.0	305
436	Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging. <i>Neurology</i> , 2015, 84, 1433-1442.	1.1	101
437	Performance of the CogState computerized battery in the Mayo Clinic Study on Aging. <i>Alzheimer's and Dementia</i> , 2015, 11, 1367-1376.	0.8	85
438	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2015, 129, 757-762.	7.7	139
439	Normative Data for 8 Neuropsychological Tests in Older Blacks and Whites From the Atherosclerosis Risk in Communities (ARIC) Study. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 32-44.	1.3	55
440	Vascular Imaging Abnormalities and Cognition. <i>Stroke</i> , 2015, 46, 433-440.	2.0	125
441	Association of hospitalization with long-term cognitive and brain MRI changes in the ARIC cohort. <i>Neurology</i> , 2015, 84, 1443-1453.	1.1	32
442	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. <i>Neurobiology of Aging</i> , 2015, 36, 2010-2017.	3.1	35
443	Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease. <i>NeuroImage</i> , 2015, 113, 61-69.	4.2	38
444	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. <i>Brain</i> , 2015, 138, 3747-3759.	7.6	170
445	Multimorbidity and Risk of Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1783-1790.	2.6	135
446	Role of $\text{A}\beta$ -Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2015, 72, 1475.	9.0	23
447	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. <i>Acta Neuropathologica</i> , 2015, 130, 863-876.	7.7	104
448	Spectrum of cognition short of dementia. <i>Neurology</i> , 2015, 85, 1712-1721.	1.1	67
449	Obesity, Insulin Resistance, and Incident Small Vessel Disease on Magnetic Resonance Imaging. <i>Stroke</i> , 2015, 46, 3131-3136.	2.0	67
450	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. <i>Acta Neuropathologica</i> , 2015, 130, 559-573.	7.7	89

#	ARTICLE	IF	CITATIONS
451	Is dominantly inherited Alzheimer disease a clone of sporadic Alzheimer disease?. <i>Neurology</i> , 2015, 85, 750-751.	1.1	2
452	Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 710-717.	0.8	461
453	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2015, 36, 452-461.	3.1	113
454	Genome-wide Studies of Verbal Declarative Memory in Nondemented Older People: The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. <i>Biological Psychiatry</i> , 2015, 77, 749-763.	1.3	67
455	Language networks associated with computerized semantic indices. <i>NeuroImage</i> , 2015, 104, 125-137.	4.2	12
456	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2015, 25, 269-274.	2.0	24
457	Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience. <i>Current Alzheimer Research</i> , 2015, 12, 607-613.	1.4	33
458	Abstract P237: Measuring Cognition in the Atherosclerosis Risk in Communities (ARIC) Study Cohort: An approach to Account for Informative Attrition. <i>Circulation</i> , 2015, 131, .	1.6	0
459	Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer's disease using the Multiple Sleep Latency Test. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 76.	6.2	45
460	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
461	Incidence of Dementia Among Participants and Nonparticipants in a Longitudinal Study of Cognitive Aging. <i>American Journal of Epidemiology</i> , 2014, 180, 414-423.	3.4	27
462	Î²-Amyloidosis and neurodegeneration in Alzheimer disease. <i>Neurology</i> , 2014, 82, 1756-1757.	1.1	15
463	Antemortem MRI findings associated with microinfarcts at autopsy. <i>Neurology</i> , 2014, 82, 1951-1958.	1.1	45
464	Association of hypometabolism and amyloid levels in aging, normal subjects. <i>Neurology</i> , 2014, 82, 1959-1967.	1.1	73
465	Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. <i>Neurology</i> , 2014, 82, 317-325.	1.1	361
466	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. <i>Journal of Neuroscience</i> , 2014, 34, 16247-16255.	3.6	117
467	Type 2 Diabetes and Cognitive Decline Over 14 Years in Middle-Aged African Americans and Whites: The ARIC Brain MRI Study. <i>Neuroepidemiology</i> , 2014, 43, 220-227.	2.3	36
468	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. <i>JAMA Neurology</i> , 2014, 71, 1547.	9.0	57

#	ARTICLE	IF	CITATIONS
469	Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. <i>Molecular Neurodegeneration</i> , 2014, 9, 38.	10.8	63
470	Association of Lifetime Intellectual Enrichment With Cognitive Decline in the Older Population. <i>JAMA Neurology</i> , 2014, 71, 1017.	9.0	160
471	Hypothyroidism and Risk of Mild Cognitive Impairment in Elderly Persons. <i>JAMA Neurology</i> , 2014, 71, 201.	9.0	48
472	Midlife Hypertension and 20-Year Cognitive Change. <i>JAMA Neurology</i> , 2014, 71, 1218.	9.0	358
473	Dementia with Lewy bodies. <i>Neurology</i> , 2014, 83, 801-809.	1.1	143
474	The Metabolic Syndrome and Cognitive Decline in the Atherosclerosis Risk in Communities Study (ARIC). <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 337-346.	1.5	26
475	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2014, 35, 1483-1490.	3.1	29
476	The neuropsychology of normal aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 84-92.	0.8	55
477	Association of diabetes with amnestic and nonamnestic mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2014, 10, 18-26.	0.8	141
478	Association of type 2 diabetes with brain atrophy and cognitive impairment. <i>Neurology</i> , 2014, 82, 1132-1141.	1.1	180
479	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. <i>Neurobiology of Aging</i> , 2014, 35, 2421.e13-2421.e17.	3.1	74
480	Progranulin protein levels are differently regulated in plasma and CSF. <i>Neurology</i> , 2014, 82, 1871-1878.	1.1	70
481	Primary age-related tauopathy (PART): a common pathology associated with human aging. <i>Acta Neuropathologica</i> , 2014, 128, 755-766.	7.7	1,060
482	Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1452-1459.	3.0	227
483	Recommendations of the Alzheimer's Disease-Related Dementias Conference. <i>Neurology</i> , 2014, 83, 851-860.	1.1	103
484	Diabetes and Elevated Hemoglobin A1c Levels Are Associated with Brain Hypometabolism but Not Amyloid Accumulation. <i>Journal of Nuclear Medicine</i> , 2014, 55, 759-764.	5.0	134
485	Dementia in MS complicated by coexistent Alzheimer disease. <i>Neurology: Clinical Practice</i> , 2014, 4, 226-230.	1.6	13
486	Age-specific population frequencies of cerebral $\beta$ -amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2014, 13, 997-1005.	10.2	297

#	ARTICLE	IF	CITATIONS
487	TDP-43 is a key player in the clinical features associated with Alzheimer's disease. <i>Acta Neuropathologica</i> , 2014, 127, 811-824.	7.7	336
488	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	10.2	302
489	Utility of the Spanish version of the FTLD-modified CDR in the diagnosis and staging in frontotemporal lobar degeneration. <i>Journal of the Neurological Sciences</i> , 2014, 344, 63-68.	0.6	16
490	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. <i>Neurobiology of Aging</i> , 2014, 35, 2096-2106.	3.1	108
491	Impact of Differential Attrition on the Association of Education With Cognitive Change Over 20 Years of Follow-up: The ARIC Neurocognitive Study. <i>American Journal of Epidemiology</i> , 2014, 179, 956-966.	3.4	102
492	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 676-685.	10.2	245
493	Association of Mediterranean Diet with Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 271-282.	2.6	540
494	Rates of $\beta^2$ -amyloid accumulation are independent of hippocampal neurodegeneration. <i>Neurology</i> , 2014, 82, 1605-1612.	1.1	119
495	P2-079: ALZHEIMER'S AND VASCULAR DISEASE-SPECIFIC STRUCTURAL BRAIN CHANGES IN CHRONIC KIDNEY DISEASE PATIENTS. , 2014, 10, P498-P499.		1
496	MRS in Early and Presymptomatic Carriers of a Novel Octapeptide Repeat Insertion in the Prion Protein Gene. <i>Journal of Neuroimaging</i> , 2013, 23, 409-413.	2.0	1
497	TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2013, 8, 19.	10.8	323
498	Anesthesia and Incident Dementia: A Population-Based, Nested, Case-Control Study. <i>Mayo Clinic Proceedings</i> , 2013, 88, 552-561.	3.0	76
499	Differences in rate of functional decline across three dementia types. <i>Alzheimer's and Dementia</i> , 2013, 9, S63-71.	0.8	34
500	MRI and MRS predictors of mild cognitive impairment in a population-based sample. <i>Neurology</i> , 2013, 81, 126-133.	1.1	95
501	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. <i>Lancet Neurology</i> , The, 2013, 12, 207-216.	10.2	3,378
502	Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2013, 12, 149-156.	10.2	204
503	Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. <i>NeuroImage: Clinical</i> , 2013, 2, 249-257.	2.7	44
504	The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62</i>	0.8	48



#	ARTICLE	IF	CITATIONS
505	Alzheimer disease biomarkers and insights into mild cognitive impairment. <i>Neurology</i> , 2013, 80, 978-980.	1.1	14
506	Brain $\beta$ -amyloid load approaches a plateau. <i>Neurology</i> , 2013, 80, 890-896.	1.1	335
507	Mild cognitive impairment due to Alzheimer disease in the community. <i>Annals of Neurology</i> , 2013, 74, 199-208.	5.3	215
508	Brain injury biomarkers are not dependent on $\beta$ -amyloid in normal elderly. <i>Annals of Neurology</i> , 2013, 73, 472-480.	5.3	155
509	Cognitive outcomes of patients undergoing therapeutic hypothermia after cardiac arrest. <i>Neurology</i> , 2013, 81, 40-45.	1.1	59
510	Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. <i>Neurology</i> , 2013, 80, 2130-2137.	1.1	46
511	Cardiac Disease Associated With Increased Risk of Nonamnesic Cognitive Impairment. <i>JAMA Neurology</i> , 2013, 70, 374.	9.0	173
512	Practice Effects and Longitudinal Cognitive Change in Normal Aging vs. Incident Mild Cognitive Impairment and Dementia in The Mayo Clinic Study of Aging. <i>Clinical Neuropsychologist</i> , 2013, 27, 1247-1264.	2.3	124
513	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. <i>Neurology</i> , 2013, 81, 1732-1740.	1.1	182
514	Patterns of Brain Atrophy in Clinical Variants of Frontotemporal Lobar Degeneration. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 35, 34-50.	1.5	42
515	Healthy young hearts sharper older minds make. <i>Annals of Neurology</i> , 2013, 73, 151-152.	5.3	3
516	Selective Worsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly Persons With $\beta$ -Amyloidosis. <i>JAMA Neurology</i> , 2013, 70, 1030.	9.0	65
517	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. <i>Brain</i> , 2012, 135, 794-806.	7.6	355
518	Comparison of Imaging Biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. <i>Archives of Neurology</i> , 2012, 69, 614.	4.5	60
519	Relative Intake of Macronutrients Impacts Risk of Mild Cognitive Impairment or Dementia. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 329-339.	2.6	133
520	Donepezil 23 mg. <i>Neurology: Clinical Practice</i> , 2012, 2, 352-355.	1.6	8
521	Multimodality imaging characteristics of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2012, 33, 2091-2105.	3.1	162
522	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. <i>Lancet Neurology</i> , The, 2012, 11, 868-877.	10.2	355

#	ARTICLE	IF	CITATIONS
523	Non-Stationarity in the "Resting Brain"™-Modular Architecture. PLoS ONE, 2012, 7, e39731.	2.5	382
524	Alzheimer's Disease and Other Dementias. , 2012, , 2274-2283.		2
525	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology, 2012, 79, 553-560.	1.1	91
526	An operational approach to National Institute on Aging's Alzheimer's Association criteria for preclinical Alzheimer disease. Annals of Neurology, 2012, 71, 765-775.	5.3	520
527	Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. Neurodegenerative Disease Management, 2012, 2, 183-195.	2.2	20
528	Diagnostic tests for Alzheimer disease. Neurology: Clinical Practice, 2012, 2, 151-153.	1.6	8
529	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	7.6	3,913
530	Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD. NeuroImage, 2011, 54, 985-991.	4.2	25
531	Effects of age and dementia on temporal cycles in spontaneous speech fluency. Journal of Neurolinguistics, 2011, 24, 619-635.	1.1	6
532	Passive case-finding for Alzheimer's disease and dementia in two U.S. communities. Alzheimer's and Dementia, 2011, 7, 53-60.	0.8	39
533	Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimer's and Dementia, 2011, 7, 80-93.	0.8	399
534	Language and behavior domains enhance the value of the clinical dementia rating scale. Alzheimer's and Dementia, 2011, 7, 293-299.	0.8	72
535	Introduction to the recommendations from the National Institute on Aging's Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 257-262.	0.8	1,547
536	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging's Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 263-269.	0.8	12,681
537	Developmental Aspects of the Intracerebral Microvasculature and Perivascular Spaces: Insights into Brain Response to Late-Life Diseases. Journal of Neuropathology and Experimental Neurology, 2011, 70, 1060-1069.	1.7	66
538	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron, 2011, 72, 245-256.	8.1	4,176
539	Estimating the Number of Persons with Frontotemporal Lobar Degeneration in the US Population. Journal of Molecular Neuroscience, 2011, 45, 330-335.	2.3	183
540	Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology, 2011, 77, 875-882.	1.1	233

#	ARTICLE	IF	CITATIONS
541	Predicting functional decline in behavioural variant frontotemporal dementia. <i>Brain</i> , 2011, 134, 432-448.	7.6	45
542	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. , 2011, 7, 263.		1
543	Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. <i>Annals of Neurology</i> , 2010, 67, 308-316.	5.3	160
544	Metabolic Syndrome, Inflammation, and Nonamnesic Mild Cognitive Impairment in Older Persons. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 11-18.	1.3	78
545	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. <i>Lancet Neurology</i> , The, 2010, 9, 119-128.	10.2	3,792
546	Vascular Risk Factors: Imaging and Neuropathologic Correlates. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 699-709.	2.6	104
547	Off-Label Medication Use in Frontotemporal Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 128-133.	1.9	57
548	Computerized Analysis of Speech and Language to Identify Psycholinguistic Correlates of Frontotemporal Lobar Degeneration. <i>Cognitive and Behavioral Neurology</i> , 2010, 23, 165-177.	0.9	48
549	Utility of the Functional Activities Questionnaire for Distinguishing Mild Cognitive Impairment From Very Mild Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 348-353.	1.3	148
550	Mild cognitive impairment associated with limbic and neocortical lewy body disease: a clinicopathological study. <i>Brain</i> , 2010, 133, 540-556.	7.6	195
551	Invited Commentary: Albuminuria and Microvascular Disease of the Brain—A Shared Pathophysiology. <i>American Journal of Epidemiology</i> , 2010, 171, 287-289.	3.4	45
552	Retinal microvascular abnormalities and subclinical magnetic resonance imaging brain infarct: a prospective study. <i>Brain</i> , 2010, 133, 1987-1993.	7.6	127
553	Validation of the Telephone Interview for Cognitive Status-modified in Subjects with Normal Cognition, Mild Cognitive Impairment, or Dementia. <i>Neuroepidemiology</i> , 2010, 34, 34-42.	2.3	245
554	Blood Pressure and White-Matter Disease Progression in a Biethnic Cohort. <i>Stroke</i> , 2010, 41, 3-8.	2.0	209
555	Retinal Microvascular Signs and 10-Year Risk of Cerebral Atrophy. <i>Stroke</i> , 2010, 41, 1826-1828.	2.0	69
556	A computerized technique to assess language use patterns in patients with frontotemporal dementia. <i>Journal of Neurolinguistics</i> , 2010, 23, 127-144.	1.1	16
557	Coronary heart disease is associated with non-amnesic mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010, 31, 1894-1902.	3.1	111
558	F1-02-01: Mayo Clinic Study of Aging. , 2010, 6, S62-S62.		0

#	ARTICLE	IF	CITATIONS
559	Association of Prior Stroke With Cognitive Function and Cognitive Impairment. Archives of Neurology, 2009, 66, 614-9.	4.5	68
560	MRI Correlates of Protein Deposition and Disease Severity in Postmortem Frontotemporal Lobar Degeneration. Neurodegenerative Diseases, 2009, 6, 106-117.	1.4	47
561	Mediterranean Diet and Late-Life Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 686.	7.4	33
562	Comparison of <sup>18</sup> F-FDG and PiB PET in Cognitive Impairment. Journal of Nuclear Medicine, 2009, 50, 878-886.	5.0	183
563	Mild Cognitive Impairment. Archives of Neurology, 2009, 66, 1447-55.	4.5	1,160
564	Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Movement Disorders, 2009, 24, 1375-1379.	3.9	105
565	Response to Letter from Dr. William Hazzard. Journal of the American Geriatrics Society, 2009, 57, 1317-1317.	2.6	0
566	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain, 2009, 132, 2932-2946.	7.6	277
567	Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain, 2009, 132, 1355-1365.	7.6	975
568	Prominent phenotypic variability associated with mutations in Progranulin. Neurobiology of Aging, 2009, 30, 739-751.	3.1	166
569	Association of C-reactive protein with mild cognitive impairment. Alzheimer's and Dementia, 2009, 5, 398-405.	0.8	111
570	Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI Study. Alzheimer's and Dementia, 2009, 5, 207-214.	0.8	199
571	Associations of microalbuminuria with brain atrophy and white matter hyperintensities in hypertensive sibships. Journal of the Neurological Sciences, 2008, 271, 53-60.	0.6	67
572	Age and apoE associations with complex pathologic features in Alzheimer's disease. Journal of the Neurological Sciences, 2008, 273, 34-39.	0.6	30
573	Argyrophilic grains: A distinct disease or an additive pathology?. Neurobiology of Aging, 2008, 29, 566-573.	3.1	70
574	Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies. NeuroImage, 2008, 39, 1186-1197.	4.2	391
575	Antemortem MRI based STructural Abnormality INdex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. NeuroImage, 2008, 42, 559-567.	4.2	152
576	Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain, 2008, 131, 2957-2968.	7.6	354

#	ARTICLE	IF	CITATIONS
577	Hippocampal Volumes, Proton Magnetic Resonance Spectroscopy Metabolites, and Cerebrovascular Disease in Mild Cognitive Impairment Subtypes. Archives of Neurology, 2008, 65, 1621-8.	4.5	75
578	Association of Duration and Severity of Diabetes Mellitus With Mild Cognitive Impairment. Archives of Neurology, 2008, 65, 1066-73.	4.5	171
579	Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem <sup>1</sup> H MR Spectroscopy Metabolite Measurements <sup>1</sup> . Radiology, 2008, 248, 210-220.	7.3	147
580	<sup>11</sup> C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. Brain, 2008, 131, 665-680.	7.6	819
581	The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics. Neuroepidemiology, 2008, 30, 58-69.	2.3	623
582	Clinical Trial Design Issues in Mild to Moderate Alzheimer Disease. Cognitive and Behavioral Neurology, 2008, 21, 197-201.	0.9	34
583	Dementia: Many roads, but not built in a day. Neurology, 2007, 69, 2193-2194.	1.1	5
584	Clinical Features of Pathologic Subtypes of Behavioral-Variant Frontotemporal Dementia. Archives of Neurology, 2007, 64, 1611.	4.5	35
585	Longitudinal Tracking of FTL. Alzheimer Disease and Associated Disorders, 2007, 21, S58-S63.	1.3	15
586	Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia (bvFTD): Current Limitations and Future Directions. Alzheimer Disease and Associated Disorders, 2007, 21, S14-S18.	1.3	219
587	Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease. , 2007, 3, 21-22.		6
588	Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying. , 2006, 2, 147-149.		6
589	Dementia and Cerebrovascular Disease. Mayo Clinic Proceedings, 2006, 81, 223-230.	3.0	67
590	Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain, 2006, 129, 1385-1398.	7.6	624
591	Current treatment of mild cognitive impairment and alzheimer's disease. Current Neurology and Neuroscience Reports, 2006, 6, 365-371.	4.2	32
592	Incidence and Causes of Nondegenerative Nonvascular Dementia. Archives of Neurology, 2006, 63, 218.	4.5	77
593	Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia. Archives of Neurology, 2006, 63, 674.	4.5	377
594	Rates of cerebral atrophy differ in different degenerative pathologies. Brain, 2006, 130, 1148-1158.	7.6	146

#	ARTICLE	IF	CITATIONS
595	Neuropathologic Features of Amnesic Mild Cognitive Impairment. Archives of Neurology, 2006, 63, 665.	4.5	562
596	Heart Disease and Dementia: A Population-based Study. American Journal of Epidemiology, 2006, 163, 135-141.	3.4	51
597	Antemortem diagnosis of frontotemporal lobar degeneration. Annals of Neurology, 2005, 57, 480-488.	5.3	181
598	Continuing the Tradition of Neuroanatomic Excellence. Journal of the International Neuropsychological Society, 2005, 11, 117-118.	1.8	0
599	Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. Neurology, 2005, 65, 876-881.	1.1	107
600	Commentary: "Treatment of hypertension and prevention of dementia" by Oliver Hanon and François Forette. , 2005, 1, 41-42.		1
601	DLB fluctuations. Neurology, 2004, 62, 181-187.	1.1	383
602	The Principle Syndromes of Dementia. , 2004, , 1216-1233.		0
603	Essentials of the Proper Diagnoses of Mild Cognitive Impairment, Dementia, and Major Subtypes of Dementia. Mayo Clinic Proceedings, 2003, 78, 1290-1308.	3.0	187
604	MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology, 2003, 60, 253-260.	1.1	279
605	Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment. Archives of Neurology, 2003, 60, 1777.	4.5	158
606	Vascular Dementia in a Population-Based Autopsy Study. Archives of Neurology, 2003, 60, 569.	4.5	194
607	Pharmacotherapy for Alzheimer's Disease: 2002. Clinical Neuropharmacology, 2003, 26, 93-101.	0.7	16
608	Survival Study of Vascular Dementia in Rochester, Minnesota. Archives of Neurology, 2003, 60, 85.	4.5	85
609	Incidence of Vascular Dementia in Rochester, Minn, 1985-1989. Archives of Neurology, 2002, 59, 1605.	4.5	66
610	Pharmacotherapy for Alzheimer's disease. Current Neurology and Neuroscience Reports, 2001, 1, 428-434.	4.2	20
611	Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology, 2001, 56, 42-48.	1.1	793
612	Patterns of Care in the Early Stages of Alzheimer's Disease: Impediments to Timely Diagnosis. Journal of the American Geriatrics Society, 2000, 48, 300-304.	2.6	139

#	ARTICLE	IF	CITATIONS
613	Dietary antioxidant intake and cognitive performance in middle-aged adults. Public Health Nutrition, 2000, 3, 337-343.	2.2	32
614	Long-term tacrine treatment effects. Neurology, 1998, 50, 567-568.	1.1	7
615	Tacrine Treatment and Nursing Home Placement: Application of the Cox Proportional Hazards Model With Time-Dependent Covariates. Drug Information Journal, 1998, 32, 729-735.	0.5	0
616	Correlates of Cognitive Function in Middle-Aged Adults. Gerontology, 1998, 44, 95-105.	2.8	237
617	Withdrawal of Neuroleptic Medications from Institutionalized Dementia Patients: Results of a Double-Blind, Baseline-Treatment-Controlled Pilot Study. Journal of Geriatric Psychiatry and Neurology, 1997, 10, 119-126.	2.3	65
618	Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs. Alzheimer Disease and Associated Disorders, 1997, 11, 13-21.	1.3	518
619	Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 1997, 11 Suppl 2, S13-21.	1.3	213
620	Long-term tacrine (Cognex) treatment. Neurology, 1996, 47, 166-177.	1.1	340
621	Progressive familial leukodystrophy of late onset. Neurology, 1996, 46, 429-434.	1.1	23
622	Tacrine for Alzheimer's Disease. Pharmacoeconomics, 1995, 7, 275-279.	3.3	9
623	Observations on the short-term 'natural history' of probable Alzheimer's disease in a controlled clinical trial. Neurology, 1994, 44, 260-260.	1.1	21
624	Characteristics of the dementia in late-onset metachromatic leukodystrophy. Neurology, 1994, 44, 662-662.	1.1	62
625	A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease. New England Journal of Medicine, 1992, 327, 1253-1259.	27.0	627
626	Long-term Retention of Implicitly Acquired Learning in Patients with Alzheimer's Disease. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1991, 13, 880-894.	1.1	69
627	Unaware learning versus preserved learning in pharmacologic amnesia: Similarities and differences.. Journal of Experimental Psychology: Learning Memory and Cognition, 1991, 17, 1017-1029.	0.9	69
628	Longitudinal Study of Death and Institutionalization in Patients with Primary Degenerative Dementia. Journal of the American Geriatrics Society, 1988, 36, 108-112.	2.6	165
629	The critical role Wernicke's area in sentence repetition. Annals of Neurology, 1985, 17, 549-557.	5.3	57
630	Computed tomographic scan correlates of auditory comprehension deficits in aphasia: A prospective recovery study. Annals of Neurology, 1983, 13, 558-566.	5.3	123



#	ARTICLE	IF	CITATIONS
631	Acute Strychnineâ€Induced Seizures in Cats:A Golgi Study. Epilepsia, 1975, 16, 791-792.	5.1	0
632	Physical Frailty and Brain White Matter Abnormalities: The ARIC Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 0, , .	3.6	4
633	CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease. Nature Reviews Neurology, 0, , .	10.1	0
634	Hypertension and Racial Differences in Dementia Reveal a Strategy for Risk Reduction in All Races. American Journal of Hypertension, 0, , .	2.0	0